Abstract
The Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 for Intermittent Claudication (TRAFFIC) is a large, randomized, placebo-controlled, regimen-finding trial of intra-arterial recombinant fibroblast growth factor-2 in patients with intermittent claudication. This report describes the major design considerations and end points in TRAFFIC.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Double-Blind Method
-
Fibroblast Growth Factor 2 / therapeutic use*
-
Humans
-
Intermittent Claudication / drug therapy*
-
Neovascularization, Physiologic / drug effects*
-
Recombinant Proteins / therapeutic use
-
Research Design
Substances
-
Recombinant Proteins
-
Fibroblast Growth Factor 2